Back to results
US 2026/0061054 A1Published application
Nanoparticles for delivery of immunoregulatory materials to t cells
AssigneeThe Johns Hopkins University
InventorsJonathan SCHNECK, Ariel ISSER, Si-Sim KANG
Life of this patent
Estimating the term…
Abstract
Artificial antigen presenting cells (aAPC) including a major histocompatibility class II (MHC II) molecule and methods of their use for identifying, isolating, or detecting one or more antigen-specific T cells, and treating a disease, disorder, or condition, including cancer, are disclosed.
Claims21
1-111. (canceled)
An artificial antigen-presenting cell (αAPC) comprising:
- (a) a particle having a major histocompatibility complex class II (MHC II) molecule conjugated to a surface thereof, and
- (b) a T-cell costimulatory ligand conjugated to the surface;
- wherein the MHC II molecule comprises an MHC II I-Ab monomer or a human leukocyte antigen (HLA) class II monomer selected from HLA-DR, HLA-DP, and HLA-DQ, the HLA class II monomer optionally being fused to an Fc domain or comprising a cysteine substitution.
A method of treating a disease, disorder, or condition in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising antigen-specific human CD4+ T cells that:
- (a) specifically recognize a peptide antigen presented by a human leukocyte antigen class II (HLA class II) molecule;
- and
- (b) express granzyme B and perform and mediate antigen-specific cytotoxicity.
Dependencies are inferred from the claim text.